二聚体 IgA 特异性失活细胞内突变的致癌驱动基因。

Dimeric IgA specifically disables intracellular mutated oncodrivers.

机构信息

MediCity Research Laboratory and InFLAMES Flagship, University of Turku, Turku, Finland.

出版信息

Immunity. 2023 Nov 14;56(11):2461-2463. doi: 10.1016/j.immuni.2023.10.014.

DOI:10.1016/j.immuni.2023.10.014

Abstract

A prevailing belief in the immunotherapy field has been that antibody therapy can effectively target only extracellular antigens. In this issue of Immunity, Biswas et al. demonstrate therapeutically effective targeting, neutralization, and removal of mutated oncodriver proteins from within epithelial cancer cells by treatment with pIgR-dependent, transcytosing dimeric-IgA antibodies.

摘要

免疫疗法领域的一个主流观点一直认为，抗体疗法只能有效地针对细胞外抗原。在本期《免疫》杂志中，Biswas 等人通过用 pIgR 依赖性的、穿越细胞的二聚体 IgA 抗体进行治疗，证明了针对突变致癌驱动蛋白的治疗性靶向、中和和清除在肿瘤上皮细胞内的效果。